Trials on trial: 'short-term pain' needed for broken clinical enterprise
This article was originally published in Scrip
A comprehensive redesign of the entire clinical trial enterprise must be considered if we are to tackle the deficit of evidence underpinning clinical practice guidelines, say researchers from Duke University in JAMA.
You may also be interested in...
Another disappointment for irritable bowel syndrome therapies as Urovant Science’s vibegron fails in a Phase II trial, likely spelling the end for the investigational indication.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.